Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059297
Filing Date
2025-04-28
Accepted
2025-04-28 16:09:05
Documents
19
Period of Report
2025-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A achv-20250424.htm   iXBRL DEF 14A 1695640
2 GRAPHIC img228350020_0.jpg GRAPHIC 4189
3 GRAPHIC img228350020_1.jpg GRAPHIC 573275
4 GRAPHIC img228350020_2.jpg GRAPHIC 573091
5 GRAPHIC img228350020_3.jpg GRAPHIC 4189
6 GRAPHIC img228350020_4.jpg GRAPHIC 934395
7 GRAPHIC img228350020_5.jpg GRAPHIC 691556
  Complete submission text file 0000950170-25-059297.txt   9357062

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20250424.xsd EX-101.SCH 13821
21 EXTRACTED XBRL INSTANCE DOCUMENT achv-20250424_htm.xml XML 475833
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 033-80623 | Film No.: 25880382
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)